Exceeding the Standards of Care
Dr. Riad Salem discusses adoption of radioembolization as the first line therapy for Hepatocellular Carcinoma (HCC). They looked at Y-90 in HCC patients across all disease stages and found that survival outcomes were either better or equivalent to other therapies. Importantly, treatment with TheraSphere resulted in better quality of life for patients. The combination of comparable or superior outcomes and a gentler treatment experience convinced them to adopt this approach.